Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vuk Zdinjak

Evogene Q2 Revenue Grows 131% YoY, Here Is What You Need To Know

Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) Q2 2022 revenue was $312,000, an increase of 131% compared to $135,000 in the same period the previous year. Revenues were primarily due to the initial sales of Lavie Bio's Thrivus product (previously branded as Result) and sales of Canonic products in the Israeli market.

Q2 2022 Financial Highlights

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.